An international research team is perfecting a method to predict the potential clinical implications of new drugs before clinical trials even start.
An international research team has developed a new strategy that can predict the potential clinical implications of new therapeutic compounds based on simple cellular responses. This discovery was partly led by scientists affiliated with Université de Montréal (UdeM), and represents a major step forward in developing more effective drugs with fewer side effects, much faster than before. The researchers conducted their work at Centre de Recherche de l’Hôpital Ste-Justine and published their findings in the prestigious journal Nature Communications.
Developing new drugs is a long, complex and costly process. It starts with identifying the molecule or “ligand” (such as a drug, hormone or neurotransmitter) that can activate or block the target or “receptor” involved in a disease. Compound identification and validation is one of the most important steps in ensuring that a new drug provides an effective clinical response with the fewest possible side effects.
“Most new drugs tested on human subjects fail in clinical trials because the therapeutic response is insufficient. Developing a strategy that infers potential clinical responses early in the drug discovery process would significantly improve drug candidate selection,” said Besma Benredjem, the study’s co-lead author and a doctoral student in pharmacology at UdeM.
Finding the needle in a haystack
“Our main goal was finding a way to categorize a large number of drug candidates based on similarities in their effectiveness in triggering a multiplicity of cellular responses that help identify the therapeutic action of new compounds,” said Professor Graciela Piñeyro, co-senior author of the study and a researcher at CHU Sainte-Justine. To accomplish this, she worked with Dr. Olivier Lichtarge of Baylor College of Medicine, who uses advanced bioinformatic analysis to compare and group ligands according to fairly comprehensive signalling profiles.
Drugs produce desired or undesired clinical actions by changing basic signals within cells. By grouping drugs with known clinical actions and new ligands, we can infer the clinical actions of new compounds by comparing the similarities and differences in their signals with known drugs to promote desired clinical responses and avoid side effects.
This method of analysis was developed by using opioid analgesics as prototypes. This made it possible for the team to associate simple cellular signals produced by opioids such as oxycodone, morphine and fentanyl with the frequency with which respiratory depression and other undesirable side effects of these drugs were reported to the Food and Drug Administration’s pharmacovigilance program. At the height of the opioid epidemic, when the risk of death by respiratory depression is at its highest, the team believes this new analytical strategy could lead to the development of safer opioids.
“Thanks to our findings, we can now classify a large number of compounds while taking a multitude of cellular signals into account. The wealth of comparisons this provides increases this classification’s predictive value for clinical responses,” said Professor Michel Bouvier, the study’s co-senior author and a principal investigator of molecular pharmacology and Chief Executive Officer of UdeM’s Institute for Research in Immunology and Cancer. “We think we can help patients by speeding up the drug discovery process so clinical trials can start earlier.”
“Our next goal is to use a similar approach to test cannabis products that may produce harmful neuropsychiatric actions among young people, and identify which cannabis extracts are most effective at treating chronic pain,” added Besma Benredjem.
The Latest on: Drug development
via Google News
The Latest on: Drug development
- JPM21: Vaccines soar, antibodies struggle as COVID-19 drugs become a businesson January 12, 2021 at 9:20 am
Moderna and Gilead reported billions in sales for their coronavirus treatments, but Regeneron's antibody drug cocktail hasn't gained traction. BioNTech, meanwhile, could report critical new vaccine ...
- Sanofi and Biond Biologics to collaborate on new cancer drugon January 12, 2021 at 8:59 am
Biond Biologics Ltd. forged an exclusive global license agreement, potentially worth more than $1 billion, with French drugmaker Sanofi for the development and commercialization of the Israeli company ...
- Shanghai Henlius Biotech Working on Covid Treatment Drugon January 12, 2021 at 8:23 am
Zhang Wenjie, chief executive officer of Shanghai Henlius Biotech Inc., a Chinese developer of biosimilar drugs, discusses the company's strategy and the outlook for the industry. Henlius said in ...
- AI-driven drug discovery collaboration to tackle neurological diseaseson January 12, 2021 at 8:18 am
Sosei Heptares and PharmEnable will harness artificial intelligence-enabled technology and advanced chemistry to explore neurological disease solutions.
- Biond Biologics sells cancer drug rights to Sanofi for $125mon January 12, 2021 at 8:05 am
Israeli biopharmaceutical company Biond Biologics announced today that it has signed an exclusive worldwide commercialization rights agreement with Sanofi for its lead product BND-22 for treating ...
- Repurposing existing drugs accelerates discovery: XenoTechon January 12, 2021 at 7:47 am
Exploring alternative uses for drugs tapped for other indications, can save considerable time and money in discovery, according to an expert from the CRO.
- Lilly's (LLY) Alzheimer's Drug Promising in Mid-Stage Studyon January 12, 2021 at 7:25 am
Eli Lilly LLY announced promising data from a phase II study — TRAILBLAZER-ALZ — evaluating its antibody candidate, donanemab, in patients with early symptomatic Alzheimer's disease (“AD”). Data ...
- Sanofi, Israel's Biond Biologics to collaborate on new cancer drugon January 12, 2021 at 5:48 am
Israel's Biond Biologics Ltd said on Tuesday it had forged an exclusive global licence agreement, potentially worth more than $1 billion, with French drugmaker Sanofi for the development and ...
- Mental Health Demand For Development Of Psychedelic Drug Therapies Is Increasingon January 12, 2021 at 5:30 am
After being relegated to the margins of sincere scientific examination for about five decades, growing researchers and scientists are ...
- Drug Development in Rare Diseases: Focus on Clinical Trials and the Regulatory Landscapeon January 11, 2021 at 2:14 am
Reportlinker.com announces the release of the report "Drug Development in Rare Diseases: Focus on Clinical Trials and ...
via Bing News